We observed alterations in MAPK pathway-related gene amplification (specifically, EGFR, FGFR1, KRAS, ERBB2, NRAS, and NGFR) in patients with ESCC (Fig. 1A). This evidence concerns the gene KRAS and esophageal squamous cell carcinoma.